EGFR and non-small cell lung carcinoma: In conclusion, for NSCLC patients with EGFR-sensitive mutations (Exon19 Del, L858R), patients treated with co-administration of EGFR-TKIs with SFI achieve more prolonged clinical benefit and longer PFS than treated with the first-generation of EGFR-TKIs alone, and SFI clinically effectively retards the occurrence of first-generation EGFR-TKIs resistance.